A year to the day after declaring the FDA’s clearance of its automated insulin pump, Sequel Med Tech announced that its first connected continuous glucose monitor will be Abbott’s FreeSty | Greenlit ...

From promising research to clinical-stage cell therapies and AI software updates, diabetes treatment and management is poised to change like never before.

(NYSE: SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot ... virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes ...

Abstract and Introduction Rationale for DPP Lifestyle Intervention Key Features of the Lifestyle Balance Intervention Conclusions References Build commitment to the DPP lifestyle change program by ...

(NYSE: SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense ® 365 Continuous ... “SweetSpot removes all the barriers to implementing a strong, virtual ...

(NYSE: SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense ® 365 Continuous ... "SweetSpot removes all the barriers to implementing a strong, virtual ...

"We are excited about the advances we are making with our diabetes gene therapy program, including the updated, consolidated exclusive license agreement with the University of Pittsburgh for ...

New Tech for Managing Type 1 Diabetes Is Effective for Older Adults Mar. 11, 2025 — New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older ...